Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-954 in critically ill patients with enteral feeding intolerance
NCT03477903Phase 2Terminated
- Sponsor
- Millennium Pharmaceuticals
- Start
- Aug 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of felcisetrag in enteral feeding intolerance (EFI), sponsored by Millennium Pharmaceuticals. Started Aug 2018; status: terminated.
02
Drugs
felcisetrag
03
Conditions
enteral feeding intolerance (EFI)
Beyond the preview
Go deeper on NCT03477903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03477903.